Pay for delay settlements have garnered enough attention in the last few years in US and Europe with the matter finally reaching the US Supreme Court for review. Although, the matter has been in much action in US, Europe has also played its part by evaluating settlements happening in EU/EEA […]
Pay for delay deals
Pay for delay settlements which have been surrounded by controversies over the past few years have now come up for review...
Pay for delay deals which have been reported earlier on SiNApSE here and here has been restricted as per the U.S. House...
EU Commission has taken steps towards investigating into Pay-For-Delay deals, which are deals entered by patent holding...
Abbott Laboratories has settled a patent dispute relating to a cholesterol drug with Teva Pharmaceuticals, which started in 1999 in USA. The settlement deal is expected to delay the release of the generic version of the cholesterol drug, Tricor, for atleast two years. As per the settlement, Abbott has given […]Read more ›
The US Senate Judiciary Committee has passed a Bill entitled “Preserve Access to Affordable Generics Act in order to restrict Pay-for-Delay settlements. The Bill aims to prevent large patent holding companies from entering into settlement agreements with generic companies in order to delay launching of equivalent and cheaper generic drugs. […]Read more ›
Ending a 3 year long difference between itself and Federal Trade Commission (FTC), the US Justice Department (DOJ) declared last week that deals between pharmaceutical companies and generic producers to delay introduction of competitive drugs must be considered illegal. Introduction of generic drugs usually causes the prices of branded drugs […]Read more ›